Biotricity, Inc. - Consolidated Statements of Operations and Comprehensive Loss - USD ($)		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Income Statement
Revenue
Expenses:
General and administrative expenses	[1]	5,961,173	4,803,918
Research and development expenses		1,762,561	1,138,252
Total Operating Expenses		7,723,734	5,942,170
Accretion expense	[2]	879,416	1,177,674
Change in fair value of derivative liabilities	[3]	20,588	689,447
Net loss before income taxes		(8,623,738)	(7,809,291)
Income taxes	[4]
Net loss		(8,623,738)	(7,809,291)
Translation adjustment		(229,745)	(333,863)
Comprehensive loss		$ (8,853,483)	$ (8,143,154)
Loss per share, basic and diluted		$ (0.286)	$ (0.302)
Weighted average number of common and exchangeable shares outstanding		30,165,638	25,866,328

[1] See Notes 9 and 10

[2] See Note 5

[3] See Note 6

[4] See Note 8